Originates in one hemisphere network. Classified by awareness level and motor/non-motor features.
Previously "partial seizures." If awareness is preserved = formerly simple partial. Impaired awareness = formerly complex partial.
Originates in and rapidly engages bilaterally distributed networks. Consciousness almost always impaired.
| Seizure Type | Key Features | Duration | Post-ictal State |
|---|---|---|---|
| Tonic-Clonic (GTCS) | Cry, rigidity (tonic), rhythmic jerking (clonic), cyanosis, urinary incontinence, tongue biting | 1–3 min | Prolonged confusion, drowsiness, headache, myalgia |
| Absence | Brief staring, unresponsive, eye flutter, no post-ictal state, abrupt onset and offset | 5–30 sec | None — immediate return to baseline |
| Myoclonic | Brief, sudden jerks — arms/shoulders/face. Often on waking. Patient may be aware. | <1 sec | Minimal or none |
| Atonic (Drop) | Sudden loss of muscle tone — collapse/fall, head drop. High injury risk. | Seconds | Brief confusion |
| Focal Aware | Motor, sensory, autonomic, or psychic symptoms; patient aware and may remember | Seconds–2 min | Variable |
| Focal Impaired Awareness | Automatisms (lip-smacking, picking), staring, post-ictal confusion, patient unaware | 30 sec–3 min | Confusion, fatigue, amnesia for event |
| Feature | Epileptic Seizure | Syncope | PNES (Pseudoseizure) |
|---|---|---|---|
| Onset | Sudden, no warning or brief aura | Usually preceded by prodrome (dizziness, nausea, greying) | Gradual, stress-related trigger often present |
| Duration | Usually <3 min | Seconds to <1 min | Often prolonged (>5 min) |
| Tongue biting | Lateral tongue bite (pathognomonic) | Tip of tongue only (rare) | Rare; may bite lip |
| Incontinence | Common | Uncommon | Can occur |
| Colour change | Cyanosis during ictus | Pallor (vasovagal) | Normal or flushed |
| Post-ictal | Prolonged confusion, headache, fatigue | Rapid recovery (<30 sec) | Variable — often crying, no true confusion |
| EEG | Ictal/inter-ictal abnormality | Normal | Normal during event on video-EEG |
| Nursing tip | Document full seizure details | Check lying/standing BP; ECG | Non-judgmental care; psychiatric referral |
Status Epilepticus Definition: Seizure lasting >5 minutes OR two or more seizures without full recovery of consciousness between them. A neurological emergency with mortality up to 20% if not treated promptly.
IV access available: Lorazepam 4mg IV (adults) — administer over 2 min. May repeat once after 10 min if no response. Child: Lorazepam 0.1 mg/kg IV.
No IV access: Buccal midazolam 10mg (adults) — first choice in community/no IV. OR Rectal diazepam 10–20mg. Child: Buccal midazolam 0.3 mg/kg (max 10mg).
Dose: 60 mg/kg IV (max 4500mg) over 10 minutes
Advantages: Fewer drug interactions, no cardiac monitoring required, safe in liver disease
Increasing first choice in GCC hospitals due to safety profile
Dose: Phenytoin 20 mg/kg IV at max 50 mg/min
Monitoring required: Continuous ECG, BP every 5 min — hypotension, bradycardia, arrhythmia risk
Fosphenytoin preferred where available (less local toxicity, faster infusion)
Dose: 40 mg/kg IV over 10 min (max 3000mg)
Avoid in pregnancy, liver disease. Effective for generalised and focal SE.
Dose: 200–400mg IV over 15 min
Emerging option; cardiac monitoring for PR prolongation. Used in some GCC tertiary centres.
Refractory SE requires ICU admission, intubation, and general anaesthesia. Call ITU/anaesthetics immediately.
1–2 mg/kg IV bolus then 2–10 mg/kg/h infusion. ICU only. Risk of propofol infusion syndrome (PRIS) with prolonged use — monitor triglycerides, lactic acidosis.
0.2 mg/kg bolus then 0.05–2 mg/kg/h infusion. Widely available in GCC ICUs. Accumulates with prolonged use.
Used for super-refractory SE. Requires EEG monitoring for burst-suppression. Significant haemodynamic side-effects.
Target: burst-suppression pattern. Neurologist/epileptologist must be involved. Consider treatable causes: autoimmune encephalitis (anti-NMDA receptor), NCSE (non-convulsive SE).
Never stop AEDs suddenly — abrupt discontinuation risks rebound seizures and status epilepticus. Always taper under neurology supervision.
| AED | Indication | Key Nursing Points | Monitoring | Teratogenicity |
|---|---|---|---|---|
| Levetiracetam (Keppra) |
Focal, generalised, adjunct | Monitor for behavioural changes — irritability, aggression, depression (5–10%). Ensure renal dose adjustment. IV and oral bioequivalent. | Renal function (dose-adjusted). Routine levels not required. | Low — Category C. Often preferred in pregnancy. |
| Sodium Valproate (Epilim) |
Generalised epilepsies (first choice), focal, absence, myoclonic | Take with food — GI side-effects. Monitor weight gain, hair thinning. Pancreatitis risk. Liver function monitoring. MHRA/GCC guidance on use in women of child-bearing age. | LFTs (first 6 months), FBC, ammonia if encephalopathic. Drug levels useful. | HIGH — Category D. Neural tube defects (spina bifida), autism spectrum disorder, developmental delay. Avoid in women of child-bearing age unless no alternative. |
| Lamotrigine (Lamictal) |
Focal, generalised, absence, Lennox-Gastaut | Slow titration essential to reduce SJS risk. Report any rash immediately — risk of Stevens-Johnson Syndrome (SJS) especially with rapid dose escalation. Levels increase in pregnancy. | Clinical monitoring for rash. Levels in pregnancy (requires dose increase). | Moderate — Category C. Preferred AED in pregnancy among available options. May increase risk of oral cleft at high doses. |
| Carbamazepine (Tegretol) |
Focal epilepsy, trigeminal neuralgia | Enzyme inducer — multiple drug interactions (contraceptives, warfarin, phenytoin). Hyponatraemia monitoring. HLA-B*1502 testing before starting in patients of Han Chinese/Thai origin (SJS risk). | FBC, LFTs, Na at baseline and 6 months. Drug levels useful (trough). ECG in elderly. | HIGH — Neural tube defects. Avoid in pregnancy if possible. |
| Phenytoin (Dilantin) |
Focal, tonic-clonic, IV acute SE | Narrow therapeutic index — toxicity at levels just above therapeutic. Signs: nystagmus, ataxia, diplopia, confusion. IV: monitor ECG, BP. Gingival hyperplasia with chronic use. Zero-order kinetics — small dose increase can cause large rise in levels. | Drug levels: therapeutic 10–20 mg/L (total); 1–2 mg/L (free). ECG during IV administration. LFTs, FBC. | HIGH — Category D. Fetal hydantoin syndrome. Avoid in pregnancy. |
GCC-specific concern: High birth rates across GCC (UAE TFR ~1.4, Saudi Arabia ~2.4, Qatar ~1.8) mean valproate prescribing in women of child-bearing age carries substantial population-level teratogenic risk.
Must be seizure-free for the legally required period before driving. Patient is legally obliged to notify licensing authority. Nurse documents this education in notes.
Consult neurologist/pharmacist before Ramadan. Once-daily AEDs: take at Iftar or Suhoor. Twice-daily: split between Iftar and Suhoor. Avoid long fasting gaps with phenytoin (erratic levels). Ensure hydration — hyponatraemia triggers seizures. Levetiracetam and lamotrigine are most flexible for Ramadan scheduling.
Epilepsy patients have a 2–6x increased risk of falls and fractures. Atonic and tonic-clonic seizures carry the highest falls risk.
| GCC Country | Seizure-Free Period Required | Authority | Notes |
|---|---|---|---|
| UAE | 2 years seizure-free (private vehicles) | RTA / Emirates Authority | Neurology clearance letter required; re-assessment annually |
| Saudi Arabia | 1–2 years (varies by condition) | MOCI / Moroor (Traffic Authority) | Consultant neurology report mandatory |
| Qatar | 2 years seizure-free | Ministry of Interior (Traffic) | Annual medical review; commercial vehicles prohibited |
| Kuwait | 2 years seizure-free | MOI Traffic Department | Neurologist clearance; HGV/PSV lifetime ban |
| Bahrain | 2 years seizure-free | General Directorate of Traffic | Medical report from treating neurologist |
| Oman | 2 years seizure-free | Royal Oman Police (Traffic) | Annual review; inform insurer |
VNS is an adjunctive neuromodulation therapy for drug-resistant epilepsy. A subcutaneous device implanted in the left chest wall delivers intermittent electrical pulses to the left vagus nerve.
Adult dose: 10mg; Child dose: by weight (0.3 mg/kg, max 10mg)
Route: Squirt between gum and cheek using applicator syringe; half each side
When to give: Seizure lasting >5 minutes OR third seizure in 24 hours without recovery
Adult dose: 10–20mg; Child: 0.5 mg/kg
Less socially acceptable in GCC cultural context — buccal midazolam is strongly preferred for community and school settings
Women with epilepsy (WWE) have higher risk of SUDEP, complications of pregnancy, and AED teratogenicity. Requires specialist multidisciplinary management from pre-conception.
| Feature | Febrile Seizure | Epilepsy |
|---|---|---|
| Trigger | Fever (>38°C) — usually viral | Not fever-related (or afebrile) |
| Age | 6 months – 6 years | Any age |
| Recurrence | 30% risk of further febrile seizure; <5% develop epilepsy | By definition recurrent unprovoked |
| EEG | Usually normal | Typically abnormal |
| Treatment | Manage fever; rectal diazepam rescue; no long-term AED | AED after second unprovoked seizure |
New-onset epilepsy in the elderly (>65 years) is the most common age group for new diagnosis. Stroke is the most common aetiology (30%).
Epilepsy developing after traumatic brain injury (TBI). Risk increases with severity of TBI, intracranial haemorrhage, depressed skull fractures, and penetrating head injuries.
GCC has among the world's highest road traffic accident (RTA) rates. Saudi Arabia, UAE, and Oman have significant TBI burdens. Nurses in trauma/neuro ICUs must be alert to early post-traumatic seizures and prophylaxis protocols.
Consanguineous marriage rates in GCC remain among the highest globally (25–55% in Saudi Arabia, Qatar, UAE). This increases the prevalence of autosomal recessive epilepsy syndromes:
In GCC: genetic epilepsy syndromes are disproportionately common. Nursing assessment should include family history of seizures, consanguinity, and developmental delay in siblings.
SUDEP occurs in approximately 1 in 1000 adults with epilepsy per year. It is the leading cause of death in people with uncontrolled epilepsy. Risk is highest in young adults with uncontrolled tonic-clonic seizures, especially during sleep.
GCC Exam Focus: High-yield content for DHA (Dubai), DOH (Abu Dhabi), SCFHS (Saudi Arabia), QCHP (Qatar), MOH Bahrain/Kuwait/Oman licensing examinations for nurses. These topics recur frequently in neurology sections.
| Time | Stage | First-Line Drug | Dose (Adult) | Route |
|---|---|---|---|---|
| 0–5 min | Stage 1 | Airway + O2 + BGL | Supportive only | — |
| 5–20 min | Stage 2 | Lorazepam (IV access) | 4mg IV over 2 min — repeat once after 10 min | IV |
| 5–20 min | Stage 2 | Midazolam (no IV) | 10mg buccal or IM | Buccal / IM |
| 20–40 min | Stage 3 | Levetiracetam IV (preferred) | 60 mg/kg (max 4500mg) over 10 min | IV |
| 20–40 min | Stage 3 | Phenytoin IV (alternative) | 20 mg/kg at max 50 mg/min + ECG monitoring | IV |
| 20–40 min | Stage 3 | Sodium Valproate IV | 40 mg/kg over 10 min (max 3000mg) | IV |
| >40 min | Stage 4 — RSE | Propofol / Midazolam infusion | ICU — anaesthesia + intubation + cEEG | IV infusion |
| AED | Mechanism | Epilepsy Type | Key Side-Effect (Exam Favourite) |
|---|---|---|---|
| Levetiracetam | SV2A binding (vesicle release inhibition) | Focal + Generalised | Behavioural changes, irritability |
| Sodium Valproate | Na channel + GABA enhancement + anti-glutamate | Generalised (1st line), Focal | Teratogenicity (HIGHEST), weight gain, tremor, hair loss |
| Lamotrigine | Na channel (voltage-gated); glutamate release inhibition | Focal + Generalised, Absence | Stevens-Johnson Syndrome (with rapid titration) |
| Carbamazepine | Na channel blockade | Focal epilepsy (NOT absence) | Hyponatraemia (SIADH), diplopia, ataxia, SJS (HLA-B*1502) |
| Phenytoin | Na channel blockade (use-dependent) | Focal + Tonic-Clonic; IV SE | Gingival hyperplasia, nystagmus, zero-order kinetics |
| Ethosuximide | T-type Ca channel blockade | Absence ONLY (first-line) | GI upset, headache |
| Phenobarbitone | GABA-A enhancement | Focal + Generalised | Sedation, dependence, enzyme inducer |